Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Selumetinib |
Indication/Tumor Type | uveal melanoma |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | uveal melanoma | not applicable | Selumetinib | Phase II | Actionable | In a Phase II trial, Koselugo (selumetinib) improved median progression-free survival (15.9 vs 7 weeks, HR=0.46, p<0.001) but not overall survival (11.8 vs 9.1 months, HR=0.66, p=0.09) compared to chemotherapy in patients with uveal melanoma, but also caused high adverse event rate (PMID: 24938562; NCT01143402). | 24938562 |
PubMed Id | Reference Title | Details |
---|---|---|
(24938562) | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. | Full reference... |